Evidence map›Paper›PMID 30165851›Full record

ArticleJournal of nanobiotechnology2018

Targeting extracellular vesicles to injured tissue using membrane cloaking and surface display.

Travis J Antes, Ryan C Middleton, Kristin M Luther, Takeshi Ijichi, Kiel A Peck, Weixin Jane Liu, Jackie Valle, Antonio K Echavez, Eduardo Marbán

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 3 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 3 syntheses or guidelines pooled it, 238 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Frontiers in immunology · 2026
    Review
  17. Review
  18. Review
  19. 80 years of extracellular vesicles: from discovery to clinical translation.Extracellular vesicles and circulating nucleic acids · 2026
    Review
  20. Review

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Travis J AntesSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building, Los Angeles, CA, 90048, USA. travantes@gmail.com.ORCID http://orcid.org/0000-0002-2294-8797
Ryan C MiddletonSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building, Los Angeles, CA, 90048, USA.
Kristin M LutherSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building, Los Angeles, CA, 90048, USA.
Takeshi IjichiSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building, Los Angeles, CA, 90048, USA.
Kiel A PeckSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building, Los Angeles, CA, 90048, USA.
Weixin Jane LiuSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building, Los Angeles, CA, 90048, USA.
Jackie ValleSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building, Los Angeles, CA, 90048, USA.
Antonio K EchavezSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building, Los Angeles, CA, 90048, USA.
Eduardo MarbánSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building, Los Angeles, CA, 90048, USA.
Cedars-Sinai Medical Center · US

Funding

Exosome-mediated cardioprotection and regenerationR01HL124074 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI MARBAN, EDUARDO · 2014 to 2021
$4.0M
National Heart, Lung, and Blood Institute R01 HL 124074NHLBI NIH HHS R01 HL124074
6 · The paper itself

Abstract

backgroundExtracellular vesicles (EVs) and exosomes are nano-sized, membrane-bound vesicles shed by most eukaryotic cells studied to date. EVs play key signaling roles in cellular development, cancer metastasis, immune modulation and tissue regeneration. Attempts to modify exosomes to increase their targeting efficiency to specific tissue types are still in their infancy. Here we describe an EV membrane anchoring platform termed "cloaking" to directly embed tissue-specific antibodies or homing peptides on EV membrane surfaces ex vivo for enhanced vesicle uptake in cells of interest. The cloaking system consists of three components: DMPE phospholipid membrane anchor, polyethylene glycol spacer and a conjugated streptavidin platform molecule, to which any biotinylated molecule can be coupled for EV decoration.

resultsWe demonstrate the utility of membrane surface engineering and biodistribution tracking with this technology along with targeting EVs for enhanced uptake in cardiac fibroblasts, myoblasts and ischemic myocardium using combinations of fluorescent tags, tissue-targeting antibodies and homing peptide surface cloaks. We compare cloaking to a complementary approach, surface display, in which parental cells are engineered to secrete EVs with fusion surface targeting proteins.

conclusionsEV targeting can be enhanced both by cloaking and by surface display; the former entails chemical modification of preformed EVs, while the latter requires genetic modification of the parent cells. Reduction to practice of the cloaking approach, using several different EV surface modifications to target distinct cells and tissues, supports the notion of cloaking as a platform technology.

Indexed as

AnimalsAntibodiesBiological TransportCell LineExosomesExtracellular VesiclesFemaleFluorescent DyesHumansMolecular Targeted TherapyNanoparticlesOptical ImagingParticle SizePeptidesPhospholipidsPolyethylene GlycolsAntibodiesFluorescent DyesPeptidesPhospholipidsPolyethylene GlycolsBiodistributionBiotinC1C2 domain fusionsCardiomyocytesEVExosomeExtracellular vesiclesHoming peptidesInfarctionIschemia/reperfusion injuryLactadherinMembrane anchorMyoblastsNanoSight NTAPhospholipidQdotsStreptavidinSurface displayTargeting antibodies

Identifiers

PMID30165851
PMCPMC6116387
OpenAlexW2889550167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.